All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @qniquephysic on TikTok · 60s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @qniquephysic's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Top three peptides to stack with retitrutide number one JHK CU because it's gonna help with your skin
  2. 0:07It's gonna help improve the elasticity
  3. 0:10Find lines and wrinkles. It's gonna help with acne scars. It's gonna help heal you a lot more quickly
  4. 0:17I
  5. 0:18Notice that my skin is just tighter overall and it makes my jaw look
  6. 0:23sharp
  7. 0:25Number two is tesamurellin because it targets your visceral fat
  8. 0:29So that's gonna give you a more aggressive cut and
  9. 0:33Number three, I would say is MT1 that stands for melanotan one
  10. 0:39That's gonna help you with tanning
  11. 0:42You'll get tanner faster. You won't need as much sun exposure because that's gonna help you get tan really fast
  12. 0:51so
  13. 0:52Those are my top three peptides that I would take with red edge rutide
  14. 0:57You

@qniquephysic's peptide claims need serious scrutiny

Dominique Clignett

TikTok creator

22.5K viewsWatch on TikTok →

Quick answer

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist currently in Phase 2 trials with no FDA approval, making any recommended stack with it entirely outside established clinical protocols. Tesamorelin carries FDA approval only for HIV-associated lipodystrophy and is not indicated for general body composition goals in healthy individuals. GHK-Cu and Melanotan 1 both lack FDA approval for any indication, and their combined use with investigational compounds like retatrutide has no published human safety data.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksGHK-Cu (Copper Peptide)Provider discussion
Start provider reviewReview GHK-Cu (Copper Peptide)

Evidence signal

Source-backed review

Regulatory reality

GHK-Cu (Copper Peptide) access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @qniquephysic's peptide claims need serious scrutiny, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Randomized trialRetatrutide evidence2023

Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial

Primary human trial source for retatrutide obesity efficacy and safety discussions.

PubMed

Randomized trialRetatrutide evidence2024

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease

Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

GHK-Cu (Copper Peptide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Start the provider review

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Helpful context before the funnel

GHK-Cu video claims video hub

Compare nearby social claims before acting.

Review GHK-Cu (Copper Peptide)

Move from claim context to product, safety, and access details.

Review method

See how FormBlends checks viral health claims.

Claim path

Keep researching this ghk-cu video claims cluster

Best for searchers checking whether GHK-Cu beauty and recovery claims match the evidence base.

View topic hubGHK-Cu video claimsReview GHK-CuTreatment or product pathRead GHK-Cu guideDeeper FormBlends guide

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@qniquephysic's peptide claims need serious scrutiny" from Dominique Clignett. We read the clip as a Peptide social video fact-checks claim about GHK-Cu (Copper Peptide), then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist currently in Phase 2 trials with no FDA approval, making any recommended stack with it entirely outside established clinical protocols.

The reason this review is not generic is the source wording and the canonical claim label "peptides retta ghkcu tesamorelin fyp peptide." In this clip, the useful excerpt is: "Top three peptides to stack with retitrutide number one JHK CU because it's gonna help with your skin It's gonna help improve the elasticity Find lines and wrinkles." That wording changes the review because it points to GHK-Cu (Copper Peptide) safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GHK-Cu (Copper Peptide) still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tesamorelin is FDA-approved (Egrifta) but only for HIV-associated lipodystrophy; Falutz et al.
People who land here are usually comparing the GHK-Cu (Copper Peptide) claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GHK-Cu (Copper Peptide) guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist currently in Phase 2 trials with no FDA approval, making any recommended stack with it entirely outside established clinical protocols.

FormBlends verdict

GHK-Cu (Copper Peptide) safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the GHK-Cu (Copper Peptide) guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist currently in Phase 2 trials with no FDA approval, making any recommended stack with it entirely outside established clinical protocols. Tesamorelin carries FDA approval only for HIV-associated lipodystrophy and is not indicated for general body composition goals in healthy individuals. GHK-Cu and Melanotan 1 both lack FDA approval for any indication, and their combined use with investigational compounds like retatrutide has no published human safety data.
  • Retatrutide remains in Phase 2 clinical trials as of 2024 and has no FDA approval; any peptide stack built around it is operating entirely without clinical safety data.
  • Tesamorelin is FDA-approved (Egrifta) but only for HIV-associated lipodystrophy; Falutz et al. (2010, Lancet HIV) documented its visceral fat effects in that specific population, not in healthy adults seeking body composition changes.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • GHK-Cu (Copper Peptide) decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the GHK-Cu (Copper Peptide) guide, cost path, safety notes, and provider review before acting.

Review GHK-Cu (Copper Peptide)

What You'll Learn

  • Retatrutide remains in Phase 2 clinical trials as of 2024 and has no FDA approval; any peptide stack built around it is operating entirely without clinical safety data.
  • Tesamorelin is FDA-approved (Egrifta) but only for HIV-associated lipodystrophy; Falutz et al. (2010, Lancet HIV) documented its visceral fat effects in that specific population, not in healthy adults seeking body composition changes.
  • GHK-Cu's skin-remodeling biology is supported by in vitro and animal data (Pickart and Margolina, 2018, Cosmetics), but published human RCT evidence for injectable GHK-Cu is sparse, and personal anecdotes about jaw sharpness are not clinical endpoints.
  • Melanotan 1 stimulates melanin production via MC1R agonism, but this does not substitute for UV photoprotection; Dorr et al. (2004, Journal of Investigative Dermatology) documented side effects including nausea and activation concerns relevant to people with moles.
  • Combining four investigational or off-label compounds simultaneously has no published pharmacokinetic or safety data in humans; the interaction profile of this stack is genuinely unknown.
  • None of the three recommended peptides have FDA approval for the uses described in this video, and tesamorelin specifically requires a prescription and clinical oversight to use legally.
  • If any of these compounds interest you, the appropriate starting point is a licensed clinician who can evaluate your individual health history, not a social media stack recommendation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @qniquephysic actually say?

The creator recommended three peptides to combine with retatrutide: GHK-Cu for skin tightening and acne scar healing, tesamorelin to "target visceral fat" for a "more aggressive cut," and Melanotan 1 (MT-1) for accelerated tanning with less sun exposure. They framed all three as personal experience stacks, noting their jaw looks "sharper" from GHK-Cu and that MT-1 means you "won't need as much sun exposure."

The framing is casual and first-person, which actually matters here. This isn't a doctor recommending a protocol. It's someone sharing what they say they personally take alongside a triple-hormone receptor agonist that is, as of 2024, still in Phase 2 clinical trials. That context is doing a lot of work that the video never acknowledges.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dominique Clignett · TikTok creator

22.5K views on this video

#retta #ghkcu #tesamorelin #fyp #peptide

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about retatrutide remains in phase 2 clinical trials as of 2024?

Retatrutide remains in Phase 2 clinical trials as of 2024 and has no FDA approval; any peptide stack built around it is operating entirely without clinical safety data.

What does the video say about tesamorelin?

Tesamorelin is FDA-approved (Egrifta) but only for HIV-associated lipodystrophy; Falutz et al. (2010, Lancet HIV) documented its visceral fat effects in that specific population, not in healthy adults seeking body composition changes.

What does the video say about ghk-cu's skin-remodeling biology?

GHK-Cu's skin-remodeling biology is supported by in vitro and animal data (Pickart and Margolina, 2018, Cosmetics), but published human RCT evidence for injectable GHK-Cu is sparse, and personal anecdotes about jaw sharpness are not clinical endpoints.

What does the video say about melanotan 1 stimulates melanin production via mc1r agonism,?

Melanotan 1 stimulates melanin production via MC1R agonism, but this does not substitute for UV photoprotection; Dorr et al. (2004, Journal of Investigative Dermatology) documented side effects including nausea and activation concerns relevant to people with moles.

What does the video say about combining four investigational?

Combining four investigational or off-label compounds simultaneously has no published pharmacokinetic or safety data in humans; the interaction profile of this stack is genuinely unknown.

What does the video say about none of the three recommended peptides have fda approval for?

None of the three recommended peptides have FDA approval for the uses described in this video, and tesamorelin specifically requires a prescription and clinical oversight to use legally.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dominique Clignett, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.